Inducing stable reversion to achieve cancer control
Nature Reviews Cancer 16, 266 (2016).
doi:10.1038/nrc.2016.12
Authors: Scott Powers & Robert E. Pollack
How can we stop cancer progression? Current strategies depend on modelling progression as the balanced outcome of mutations in, and expression of, tumour suppressor genes and oncogenes. New treatments emerge from successful attempts to tip that balance, but secondary mutational escape from those treatments has (Source: Nature Reviews Cancer)
Source: Nature Reviews Cancer - March 3, 2016 Category: Cancer & Oncology Authors: Scott PowersRobert E. Pollack Tags: Perspectives Source Type: research
Leukaemia 'firsts' in cancer research and treatment
Nature Reviews Cancer 16, 163 (2016).
doi:10.1038/nrc.2016.3
Author: Mel Greaves
Our understanding of cancer biology has been radically transformed over recent years with a more realistic grasp of its multilayered cellular and genetic complexity. These advances are being translated into more selective and effective treatment of cancers and, although there are still considerable challenges, particularly (Source: Nature Reviews Cancer)
Source: Nature Reviews Cancer - February 25, 2016 Category: Cancer & Oncology Authors: Mel Greaves Tags: Perspectives Source Type: research
The molecular pathogenesis of chronic lymphocytic leukaemia
Nature Reviews Cancer 16, 145 (2016).
doi:10.1038/nrc.2016.8
Authors: Giulia Fabbri & Riccardo Dalla-Favera
Recent investigations have provided an increasingly complete picture of the genetic landscape of chronic lymphocytic leukaemia (CLL). These analyses revealed that the CLL genome displays a high degree of heterogeneity between patients and within the same patient. In addition, they highlighted molecular mechanisms and functionally (Source: Nature Reviews Cancer)
Source: Nature Reviews Cancer - February 25, 2016 Category: Cancer & Oncology Authors: Giulia FabbriRiccardo Dalla-Favera Tags: Review Source Type: research
Antitumour actions of interferons: implications for cancer therapy
Nature Reviews Cancer 16, 131 (2016).
doi:10.1038/nrc.2016.14
Authors: Belinda S. Parker, Jai Rautela & Paul J. Hertzog
The interferons (IFNs) are a family of cytokines that protect against disease by direct effects on target cells and by activating immune responses. The production and actions of IFNs are finely tuned to achieve maximal protection and avoid the potential toxicity associated with excessive responses. (Source: Nature Reviews Cancer)
Source: Nature Reviews Cancer - February 25, 2016 Category: Cancer & Oncology Authors: Belinda S. ParkerJai RautelaPaul J. Hertzog Tags: Review Source Type: research
Immunotherapy: Biomarkers of immunotherapy-induced colitis
Nature Reviews Cancer 16, 129 (2016).
doi:10.1038/nrc.2016.22
Author: Sarah Seton-Rogers
Despite the therapeutic efficacy of immune checkpoint inhibitors against some tumours, immune-related side effects remain a large concern. Dubin et al. show in a prospective study of patients with melanoma that new-onset colitis associated with the cytotoxic T lymphocyte-associated antigen 4 (CTLA4) inhibitor ipilimumab (Source: Nature Reviews Cancer)
Source: Nature Reviews Cancer - February 25, 2016 Category: Cancer & Oncology Authors: Sarah Seton-Rogers Tags: Research Highlight Source Type: research
